Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FLURAZEPAM

All products: general benefit

Other products in the same Health Canada class (N05C, N05CD) — coverage varies; not interchangeable

  • Nitrazepam (Mogadon): general benefit
  • Temazepam (Restoril): general benefit
  • Triazolam (Halcion): general benefit, Not a benefit
  • Midazolam (Versed): limited Use 495, 496, Not a benefit
  • Eszopiclone (Lunesta): not a benefit
  • Zolpidem (Sublinox): not a benefit

1 more in the class list below

Flurazepam · DIN 00521701 · 30mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Flurazepam · DIN 00521701 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2015-05-06 · brand FLURAZEPAM · ATC N05CD01 FLURAZEPAM · form Capsule · route Oral · ingredients FLURAZEPAM HYDROCHLORIDE 30 MG · company Aa pharma inc · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Flurazepam: Formulary list price $0.1364/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1364 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4729 · Verify on the e-Formulary ↗ (DIN 00521701)

Source record
DIN 00521701: Flurazepam Raw flags: sec3=Y Item: 282400015; group id 521; item number 1411; lccId None; manufacturer id AAP Source form: Cap; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $0.1364; ministry $0.1364 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00521701 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4729
Interchangeable products
Dalmane · DIN 00012718 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00521701
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:24 Sedatives and Hypnotics) and how they are covered

Matched class: 28:24 Sedatives and Hypnotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: NITRAZEPAM, PHENOBARBITAL, TEMAZEPAM Some products covered without a code (check the product listing): BUSPIRONE HYDROCHLORIDE, METHOTRIMEPRAZINE, TRIAZOLAM 28:24 Sedatives and Hypnotics

NITRAZEPAM

· 2 products · General benefit · strengths: 5mg, 10mg · Tab

TEMAZEPAM

· 2 products · General benefit · strengths: 15mg, 30mg · Cap

TRIAZOLAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.125mg, 0.25mg · Tab

MIDAZOLAM

· 3 products · Listed, not a benefit (1), Limited Use, codes 495, 496 (2) · strengths: 5mg/mL · Inj Sol (with Preservative)

ESZOPICLONE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 3mg · Tab

ZOLPIDEM TARTRATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · SL Tab

ZOPICLONE

· 40 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3.75mg, 5mg, 7.5mg · Tab

BUSPIRONE HYDROCHLORIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 10mg · Tab

METHOTRIMEPRAZINE

· 9 products · General benefit (5), Listed, not a benefit (4) · strengths: 25mg/mL, 2mg, 5mg, 25mg, 50mg · Inj Sol-1mL Pk, Tab

PHENOBARBITAL

· 5 products · General benefit · strengths: 5mg/mL, 15mg, 30mg, 60mg, 100mg · Oral Elixir, Tab

LORAZEPAM

· 9 products · Listed, not a benefit (1), Limited Use, codes 481 (2), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 4mg/mL, 0.5mg, 1mg, 2mg · Inj Sol (with preservative), SL Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:24
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS FLURAZEPAM (flurazepam hydrochloride) is indicated for the symptomatic relief of transient and short- term insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakening. The use of hypnotics should be restricted for insomnia where disturbed sleep results in impaired daytime functioning. 1.1 Pediatrics Pediatrics (<15 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of FLURAZEPAM in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. (see 7.1.3 Pediatrics) 1.2 Geriatrics Geriatrics: Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. Long-term use of FLURAZEPAM should be avoided in elderly patients. Enhanced monitoring is recommended (see Falls and Fractures; 4.1 Dosing Considerations). https://pdf.hres.ca/dpd_pm/00063186.PDF PM date: December 31, 1982 Source product: FLURAZEPAM; DIN 00521698; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.